Objectives. The aim of this study was to identify the factors that play a role for patients with RA when considering dose reduction (i.e. gradual tapering until discontinuation) of biological DMARDs (bDMARDs), and to determine their relative importance.
Introduction
Biological DMARDs (bDMARDs) are effective and safe in the treatment of RA [1] . However, their use is also associated with side-effects, high costs and practical burden for patients (e.g. self-injection, storing medication) [24] . Dose reduction (i.e. gradual tapering until discontinuation) of bDMARDs, after low disease activity is reached, is proven to be safe and non-inferior to continuation [5, 6] . Therefore, dose reduction is recommended in current (inter)national guidelines [7, 8] .
To date, only two small studies have focused on (b)DMARD dose reduction from the perspective of the patient [9, 10] . Markusse et al. performed a structured interview study among 20 RA patients to explore their opinion about tapering and discontinuing of anti-rheumatic drugs in general. This study provided information on patients' positive and negative expectations of dose reduction (e.g. hope, happiness and relief versus fear and disappointment) but, due to the structured design of the interviews, failed to explore all themes/concepts that may play a role among patients when considering tapering themselves [9] . Furthermore, Wallis et al. performed a focus group with nine patients with RA on their concerns and attitudes towards dose reduction. The main concerns they found were loss of disease control, delay in access to the previous dose and potential loss of efficacy of a previously successful treatment. Perceived benefits were a lower risk of adverse effects and reduced frequency of injection [10] .
These small studies provide useful information on attitudes and expectations of patients, however verification of their results in a larger sample is warranted and information on which factors are most important for patients is still lacking. Therefore, the primary aim of this study was to identify the factors that play a role for patients when considering dose reduction of bDMARDs, and to determine their relative importance. The secondary objective was to investigate the influence of patient characteristics (e.g. age, gender, disease duration) on the ranking of factors, as it is conceivable that subgroups of patients have different preferences [11, 12] .
Methods
A mixed methods design was used consisting of two consecutive sub studies. Both studies were presented to the Medical Ethical Committee of the region ArnhemNijmegen (file numbers 2015-1845 and 2016-2559). An exemption was obtained, as ethical approval for these types of studies is not required under Dutch law. This study complies with the declaration of Helsinki and all patients gave their written informed consent for participation.
Sub study 1
To gain insight into the influencing factors as perceived by patients, semi-structured interviews were performed to explore attitudes and experiences in health care [13] .
Recruitment of participants
For the interviews, we recruited patients from the rheumatology department of a hospital specialized in disorders of posture and movement (rheumatology, orthopaedics and rehabilitation medicine) in the Netherlands (Sint Maartenskliniek), by purposive sampling [13] . This means that we aimed to include a variety of patients looking at type of bDMARD (including mode of administration), treating rheumatologist and experience with dose reduction of a bDMARD, to get insight into the whole range of experiences and attitudes on bDMARD dose reduction. Patients had to be 518 years, diagnosed with RA (clinical diagnosis), using (or having used) a bDMARD and able to communicate well in Dutch. Patients were selected by the researchers (L.M.V., A.A.dB.) and approached by their rheumatologist during an outpatient visit. Recruitment of patients was stopped when data saturation was reached (no new information emerging from the last three interviews).
Interviews
A semi-structured interview guide was developed (using the framework of Flottorp [14] , a checklist for identifying factors that prevent or enable improvements in health care). This guide focused on the experience with tapering and discontinuing bDMARDs, the barriers and facilitators regarding bDMARD dose reduction and preferences and suggestions for optimal implementation of bDMARD dose reduction. Telephone interviews (unless the patient preferred a face-to-face interview) were performed by one researcher (L.M.V.). All interviews were audio-recorded and transcribed verbatim. A summary of the interview was sent to the interviewee to assure the validity of the data (member check).
Analysis
The transcribed interviews were analysed by inductive thematic analysis using the qualitative data analysis software MAXqda (version 11). Three analysis steps were used: open, axial and selective coding [15] . Two researchers (L.M.V., E.M.H.S.) analysed the first six transcripts separately. All other transcripts were coded by one researcher (L.M.V.) and checked by a second researcher (E.M.H.S.). Differences were discussed until consensus was reached and if necessary, the codebook was adapted (adding, removing or changing codes). Results and saturation were discussed during the process.
The result of the inductive thematic analysis was a list of barriers and facilitators that was afterwards summarized into factors that play a role for RA patients when considering dose reduction [neutrally formulated from the patient perspective by consensus among two researchers (L.M.V., E.M.H.S.) and one researcher/rheumatologist (A.A.dB.)].
Sub study 2
To investigate the relative importance of the factors from the interview study, we used a Maximum Difference Scaling (MaxDiff) survey. MaxDiff produces preference scores for multiple factors. Respondents are shown several subsets of the possible factors in the questionnaire and are asked to indicate (among this subset) the most and least important factor [16] . This method simplifies the ranking task for participants, enables discrimination between ratings of different factors involved in complex decisions and is not influenced by scale related biases [16, 17] . The MaxDiff method was successfully used for similar studies in rheumatology [18, 19] .
Recruitment of participants
For MaxDiff, there is no formal sample size calculation available [20] . Based on other MaxDiff studies and following the advice of a statistician, we decided on a minimum of 100 respondents needed for a reliable assessment of preferences with the MaxDiff questionnaire. Because we also wanted to explore the influence of several patient characteristics, we aimed to include 200 patients in total. Patients were selected from the electronic patient files and from trials that had been performed into bDMARD dose reduction. Patients were screened for eligibility and approached for the study with a letter on behalf of their rheumatologist in random order. Permission of the treating rheumatologists was asked before patients were approached. One reminder was sent in case patients did not respond.
Patients were recruited at the rheumatology department of three different medical centres in the Netherlands (an academic hospital, a hospital specialized in disorders of posture and movement and a general hospital). Patients had to be 518 years, diagnosed with RA, using (or having used) a bDMARD, should have basic computer skills and an email address, and should be able to read and write in Dutch. Patients that had no experience with dose reduction additionally needed to have low disease activity during the last visit to the hospital (DAS28CRP < 2.9/ DAS28ESR < 3.2 or judgement of rheumatologist) so the option of dose reduction would be better conceivable.
Designing the survey
The MaxDiff questionnaire was designed and fielded using the Sawtooth Software's Lighthouse Studio (version 9.3.1). The MaxDiff exercise consisted of 18 questions in which five factors were shown to ensure that every respondent would rank every factor three times (18 Â 5/ 30 = 3). An example of a MaxDiff question is shown in Fig. 1 . Questions on patient characteristics (gender, age, hospital, disease duration, number of bDMARDs used, experience with dose reduction and attitude towards dose reduction) were added to the survey. The final questionnaire was tested by two patients with RA to ensure all items were understandable and to determine the time needed to complete the survey.
Analyses
The MaxDiff software produced a utility (preference score) for every factor in the survey. The higher the utility, the more likely the factor was chosen as most important (and not as least important). Using Hierarchical Bayesian methods, the software estimated individual level utilities by combining information from individuals' specific choices with the distribution of utilities across participants. Average scores were generated by iteration. To facilitate interpretation, the scores were subsequently rescaled to a Rescaled Probability Score (RPS) on a scale from 0 to 100; the higher the score, the more important the factor. For example, a factor with an RPS of 5 is twice as important as a factor with an RPS of 2.5 [17] . In our study, these scores represent the relative importance of a factor for patients considering bDMARD dose reduction. Patients that gave inconsistent answers on the MaxDiff questionnaire (Root Likelihood below the recommended cut-off of 0.269 [21] ) were excluded from the analyses.
We investigated whether there were any differences between patient groups in the RPS scores by descriptive statistics and linear regression analyses. We selected the most important factors by taking a cut-off at half of the highest RPS [19] . With descriptive statistics we compared the most important factors of patients from different subgroups (age divided by 465/>65 years, disease duration by 410/>10 years and number of biologicals by 1/>1). Next to this, several linear regression models were made using the RPS as the dependent variable and the seven characteristics as independent variables. Dependent variables were transformed when data were not normally distributed (judged by histograms and skewness/kurtosis) and homoscedasticity was investigated with the Breusch-Pagan/Cook-Weisberg test. All statistical tests were performed with STATA (version 13.1) and corrected for multiple testing by dividing the significance level a (0.05) by the number of regression models that were made (Bonferroni correction).
FIG. 1 Example of a MaxDiff question
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Results

Sample characteristics
For sub study 1, saturation was reached when 22 patients were interviewed (after 30 patients were invited, response rate 73%). For sub study 2, 444 patients were invited and 195 completed the survey (response rate 44%, see Fig. 2 for flowchart of inclusion). Of the 100 patients that indicated they did not want to participate, 42 mentioned a reason for this; the two most frequently mentioned reasons were no computer/email address (n = 11) and not wanting to taper the bDMARD, thus misunderstanding the objective of the study (n = 19). Table 1 shows the characteristics of the participants for both sub studies. Most respondents were female, mean age was around 60 and most patients had established RA (long disease duration). Of respondents in the MaxDiff survey, 61% indicated that they had experience with dose reduction of a bDMARD and 73% of patients were positive or very positive about dose reduction in case of low disease activity. The ratio between patients that were positive/very positive about dose reduction and negative/very negative about dose reduction did not differ substantially between patients with and without experience with dose reduction: 91/ 8 = 11.4 for patients with experience and 50/5 = 10 for patients without experience (data not shown). Three patients had a Root Likelihood below 0.269 and were therefore excluded from the analyses.
Sub study 1
The interviews provided a broad overview of all the factors that play a role for patients when considering dose reduction and inductive thematic analysis resulted in a list of 43 barriers and facilitators within nine themes. These themes were: disease activity, functioning/pain, adverse effects, practical use of the bDMARD, attitude towards medication, previous experience(s) with dose reduction, social aspects, organizational aspects and costs. Table 2 shows two exemplary quotes from interviewees per theme. The 43 barriers and facilitators were summarized into 30 factors that were used in the MaxDiff survey.
Sub study 2
Ranking of factors
The 30 factors and their RPS are shown in Table 3 . The three highest ranked factors were: '27. The possibility to increase the dose when disease symptoms worsen'; '2. The risk that my disease activity will increase'; and '1. 
Differences in ranking between patient groups
Using a cut-off value of 4.06 (half of the highest RPS), a top-13 of most important factors was selected (number 1, 2, 3, 4, 5, 7, 11, 13, 14, 16, 17, 19 and 27) . For these factors, we investigated whether several patients' characteristics were associated with the RPS. With descriptive statistics we found that the group of factors in the top-13 was consistent between all subgroups except for attitude For the regression analyses, we investigated the distribution of the 13 most important factors. Eight of them showed a sufficiently normal distribution. The five remaining factors (number 2,3,7,13 and 27) were subjected to the most suitable transformation (square, cube or square root). Thirteen regression models were made based on records with informative data on all variables (excluding patients that answered 'I do not know' for experience with dose reduction, and/or 'I do not know' or 'neutral' on attitude towards dose reduction) (n = 154) and P-values of the coefficients were investigated using an a of 0.05/ 13 = 0.0038.
The regression models showed that gender, age, hospital, experience with dose reduction and attitude towards dose reduction were associated with one or more of the 13 factors (see Table 4 ). Disease duration and number of bDMARDs used were not significantly associated with any of the top-13 factors.
Discussion
In this mixed methods study, most RA patients indicated that they are positive towards bDMARD dose reduction when low disease activity is reached. However, patients are mainly concerned that dose reduction will lead to a disease flare that affects their daily life (pain, function). It is important for them to know that they can increase the dose if (further) reduction is not possible and that the bDMARD will be effective again. Patients value the opinion of their rheumatologist, and being involved in the decision to start tapering is highly ranked as well. With explorative linear regression modelling, we found that age, gender, experience with dose reduction, attitude towards dose reduction and hospital setting seem to influence the importance of some factors. However, the 13 most important factors were very consistent throughout different patient groups, which makes us conclude that the overall ranking of factors found in this study is quite robust and valid for a large group of RA patients. This study confirms the results from earlier small studies on this subject that found that most patients are positive about bDMARD dose reduction but fear a disease flare and have concerns about being able to return to higher dosages [9, 10] . Our results are also consistent with the barriers and facilitators that were found in a systematic review on deprescribing in general [22] . Furthermore, the importance of the rheumatologist's opinion and a patient's trust in him/her was also shown by Martin et al. [23] and van Hulst et al. [18] and the wish of patients to be involved in decisions on DMARD changes is consistent with the findings of Nota and colleagues [24] .
Studies into the attitude of patients to bDMARD medication show that patients are generally very positive about the effect of bDMARDs [25, 26] and reluctant to changes in DMARD treatment [27] . When looking at overcoming the barriers that are perceived by patients, the results of this study might be used to inform care providers on the topics that are most important for patients. During consultations, care providers should address possible fears and concerns and put these in context with recent evidence on dose reduction. Through this, shared decision making on bDMARD dose reduction and implementation of this principle can be stimulated. Furthermore, the most important topics that were found in this study could be included in patient information on bDMARDs, to prepare patients on the option of dose reduction and adjust expectations from the start of bDMARD use. Other possibilities are to incorporate the (most important) topics in a tool or questionnaire for patients to elicit their preferences and prepare for a consultation in which dose reduction is discussed, or a tool for both patients and Values are presented n (%) unless otherwise stated. bDMARD: biological DMARD.
https://academic.oup.com/rheumatology health care providers that might be used during consultation (e.g. a decision aid). This study has several strengths. It is the first study with a considerable sample size looking into bDMARD dose reduction from the patient perspective. Furthermore, the mixed methods design and recruitment of patients in different (type of) centres improves the generalizability of our results. A possible weakness of our study might be the rephrasing of the factors for the MaxDiff questionnaire by the research team. However, we consider the risk of misunderstandings low, as the factors were derived from interviews with patients and tested by two patients to ensure understandability. Also, this type of research inevitably relies on self-reported factors, whereas there might be other influencing factors of which patients are unaware, or that are not mentioned due to social desirability.
Next to this, some selection bias might be present, as the response rate in sub study 2 was 44%. However, our sample seems to be representative for the general RA population. Furthermore, the results we found might not be generalizable to patients from other countries with, for example, other cultural values, reimbursement systems or traveling distances to the hospital. Therefore, it is important to replicate this study in different settings and when possible with a longitudinal design to be able to investigate attitudes over time. Finally, assessing the influencing factors from the perspective of health care providers would also be important to facilitate implementation of bDMARD dose reduction. For future studies on this topic, we recommend recruiting patients in a face-toface manner to increase response rate and avoid misunderstanding of the study objective. On the one hand I am glad that these medicines exist, on the other hand, er, . . . they may likely cause side effects in the future. It did [the bDMARD] have one negative effect: it reduced my resistance. When I had a cold, for example, I could not fight it off. So I had to take a course of penicillin to get better. 4. Practical use of the bDMARD . . . and in the beginning you just can't do it, it's scary to do it yourself.
[injecting yourself with a bDMARD] You must keep it refrigerated. Next week I will go on a holiday and then I will take two syringes with me. If you are going on a long trip, you must put them in a small fridge. 5. Attitude towards medication I take multiple medications and I often think about how to reduce the use of these medications. I make that assessment almost every day. But on the other hand: life is in constant motion. You can no longer say: you have a job for the rest of your life. Likewise, you can no longer say: you are on medication for the rest of your life. It doesn't work like that anymore. And, er, I accept that this is constantly changing. 6. Earlier experiences with bDMARD dose reduction I am afraid I will always need some medication. I did try to stop using anything at all one time and this ended up being a disaster. So I have already had that experience. Maybe it's just the feeling. The fact that you have cut back on your medication also changes your mind-set. At the moment you stop taking your medication you have the feeling that you are a little healthier. It's a kind of small victory. In conclusion, patients with RA are positive about the option of bDMARD dose reduction in case of low disease activity but perceive several barriers and facilitators. This study shows that a major concern of patients is a possible increase in disease activity and its influence on pain and function. Next to this, it is important for patients to know they can return to a higher dose if (further) reduction fails and that the bDMARD will be effective again. These results are important to facilitate implementation of bDMARD dose reduction and can be used in clinical practice as a starting point for shared decision making. Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.
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